Alkermes (ALKS) Interest & Investment Income (2010 - 2026)
Alkermes' (ALKS) quarterly Interest & Investment Income came in at -$568000.0 in Q1 2026, down 210.94% year-on-year from $512000.0 in Q1 2025, and up 98.29% on a QoQ basis from -$33.3 million in Q4 2025.
Alkermes (ALKS) Interest & Investment Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Interest & Investment Income data on file, last reported at -$568000.0 in Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 210.94% year-over-year to -$568000.0 in Q1 2026; TTM through Mar 2026 was -$33.5 million, a 470.06% decrease from a year earlier, with the FY2025 full-year figure at -$133000.0, down 111.64% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$568000.0, up from -$33.3 million in the prior quarter.
- Over the last five years, Interest & Investment Income for ALKS reached as high as $16.7 million in Q4 2022 and fell as low as -$33.3 million in Q4 2025.
- Historically, Interest & Investment Income has averaged -$88705.9 across 5 years, with a median of $55000.0 in 2025.
- Across the five-year window, Interest & Investment Income jumped 498.89% in 2023 and slumped 1292.43% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $16.7 million in 2022, then sank by 82.3% to $3.0 million in 2023, then plunged by 180.7% to -$2.4 million in 2024, then slumped by 1292.43% to -$33.3 million in 2025, then surged by 98.29% to -$568000.0 in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were -$568000.0 in Q1 2026, -$33.3 million in Q4 2025, and $341000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Alkermes | 8.78 Bn | 8.26 Bn | 331.33 Mn | -568,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -568,000.00 |
| Dec 31, 2025 | -33.31 Mn |
| Sep 30, 2025 | 341,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 512,000.00 |
| Dec 31, 2024 | -2.39 Mn |
| Sep 30, 2024 | 10.92 Mn |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | -491,000.00 |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Jun 30, 2023 | 692,000.00 |
| Mar 31, 2023 | 2.76 Mn |
| Dec 31, 2022 | 16.74 Mn |
| Sep 30, 2022 | -2.35 Mn |
| Jun 30, 2022 | -2.25 Mn |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | -4.33 Mn |
| Sep 30, 2021 | -249,000.00 |
| Jun 30, 2021 | -272,000.00 |